San Diego County Regional Public Safety Agencies Launch Genasys EVAC for Enhanced Emergency Communication

Written by Customer Service on May 30, 2024. Posted in Public Companies.

genasys image SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in Protective Communications, is pleased to announce that the San Diego County regional area announced yesterday at a press conference the official launch of Genasys Protect EVAC, a cutting-edge emergency alerting solution that will enable citizens to receive timely updates during emergency situations. With peak fire conditions looming ahead, this region wide collaboration aims to bolster emergency communication efforts and ensure the safety of all residents. EVAC, which is currently deployed across 70% of California, will serve as the primary tool for quickly disseminating critical public safety information, including severe weather alerts, evacuation notices, missing person reports, and other essential updates to affected...

NowVertical Group Reports First Quarter 2024 Financial Results

Written by Customer Service on May 30, 2024. Posted in Earnings Releases And Operating Results.

Q1 2024 Revenue was $12.9 million, an increase of 3% over Q1 2023 Q1 2024 Income from Operations was $0.2 million, an increase of 120% over Q1 2023 Q1 2024 Adjusted EBITDA was $1.6 million, an increase of 314% over Q1 2023 TORONTO, May 30, 2024 (GLOBE NEWSWIRE) — NowVertical Group Inc. (TSX-V: NOW) (OTCQB: NOWVF) (“NOW” or the “Company”), a leading data analytics and AI solutions company, today announced its financial results for the three months ended March 31, 2024. “We made significant progress in the first quarter on multiple fronts, including leadership and governance, reconfiguring our go-to-market strategy, and implementing an aggressive strategic integration and restructuring plan,” said Sandeep Mendiratta, CEO of NOW. “This quarter was a transitional period as we initiated implementation of our One...

Hydreight Reports Record Topline(1) Revenue of $4.87M in Q1-2024 (YOY Increase of 33%)

Written by Customer Service on May 30, 2024. Posted in Earnings Releases And Operating Results.

“We had an outstanding quarter with record revenue…Our focus in 2024 is to continue growing revenue, becoming a profitable company and introducing our story to more potential shareholders” – Shane Madden, CEO of Hydreight VANCOUVER, British Columbia and LAS VEGAS, May 30, 2024 (GLOBE NEWSWIRE) — Hydreight Technologies Inc. (“Hydreight” or the “Company”) ( TSXV: NURS )( OTCQB: HYDTF )( FSE: SO6 ), a fast-growing mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United States, is pleased to announce its financial results for the first quarter ended March 31, 2024. All financial information is presented in Canadian dollars unless otherwise indicated. Summary of Q1, 2024 Financial Highlights: Q1, 2024 GAAP revenue was $3.38 million an increase of 44% compared...

Patagonia Gold Quarter 1 2024 Financial Results

Written by Customer Service on May 30, 2024. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) — Patagonia Gold Corp. (“Patagonia” or the “Company”) (TSXV: PGDC) announces its financial results for the quarter ended March 31, 2024 (“Q1 2024”). The financial statements together with the related management’s discussion and analysis are available on the Company’s website and under the Company’s profile on SEDAR+ at www.sedarplus.ca. Highlights Generated revenue of US$1.8 million in Q1 2024. Produced 636 gold equivalent ounces(1) and sold 850 gold equivalent ounces(1) in Q1 2024. Incurred exploration expenditures of US$0.8 million in Q1 2024 including completion of: Mapping and sampling on the La Valencia project and a total of 384-line kilometers of ground magnetics surveying to the east of Veta Principal (the main structure on the project). A diamond drilling program...

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

Written by Customer Service on May 30, 2024. Posted in Public Companies.

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced presentations of data from its preclinical and healthy volunteer studies of briquilimab, as well as trial-in-progress presentations from its BEACON and SPOTLIGHT clinical studies, at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain. The two preclinical studies being presented at EAACI showed the potential of briquilimab in asthma and atopic dermatitis (AD), respectively. The asthma...

Central 1 reports 2024 first quarter financial results

Written by Customer Service on May 30, 2024. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) — Central 1 Credit Union (Central 1) today reported its first quarter performance reflecting strong financial results across business lines consistent with plans and expectations. “Central 1’s financial performance for the first quarter of 2024 remained stable,” said Sheila Vokey, Central 1’s President and CEO. “As we continue to monitor market forces and trends, our internal efforts remain focused on providing access to reliable services and core support for our members and clients.” First quarter 2024 compared with first quarter 2023: Net income of $28.9 million, compared with net income of $1.3 million Net fair value gain1 of $34.5 million, compared with net fair value loss1 of $6.2 million Net interest income of $14.5 million, compared with net interest income of $11.9...

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

Written by Customer Service on May 30, 2024. Posted in Public Companies.

Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers QIAGEN to make kit-based HRD test available globally to support research and companion diagnostics development in collaboration with pharmaceutical partners enabling wider adoption and potential clinical indication expansion for MyChoice CDx Project builds on recently announced master collaboration agreement between the two companies VENLO, The Netherlands and SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency...

Plug to Webcast Annual Shareholder Meeting on June 5, 2024

Written by Customer Service on May 30, 2024. Posted in Public Companies.

LATHAM, N.Y., May 30, 2024 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, invites investors and the general public to listen to a webcast of its annual meeting of stockholders on Wednesday, June 5, 2024, at 10:00 a.m. Eastern Time. The live webcast can be accessed through the Internet at www.virtualshareholdermeeting.com/PLUG2024. A general corporate overview and question and answer session is expected to follow the business portion of the annual meeting. The webcast can also be accessed directly from the Plug homepage (www.plugpower.com). A playback of the webcast will be available at www.plugpower.com for a period of time following the meeting. Stockholders of record will be able to submit questions on the day of the meeting in writing through...

Rakovina Therapeutics Announces 2024 Q1 Financial Results and Provides Corporate Update

Written by Customer Service on May 30, 2024. Posted in Earnings Releases And Operating Results.

All dollar amounts reflected in Canadian dollars unless otherwise stated VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX.V: RKV), (the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the first quarter of 2024 ending March 31, and provides an update to corporate activities. “This year has started with significant changes for Rakovina Therapeutics in the most positive sense,” said Executive Chairman Jeffrey Bacha. “Our strategic shift to include AI in our drug developments, additions to the scientific team and expansion of our research collaborations all position Rakovina Therapeutics to successfully achieve our goal of improving the lives of patients with cancer.” Q1...

HashiCorp Announces First Quarter of Fiscal Year 2025 Financial Results

Written by Customer Service on May 30, 2024. Posted in Earnings Releases And Operating Results.

First quarter revenue totaled $160.6 million, representing an increase of 16% year-over-year. Trailing four quarter average Net Dollar Retention Rate was 113% at the end of the first quarter of fiscal 2025 as compared to 127% at the end of first quarter of fiscal 2024. First quarter GAAP RPO totaled $748.5 million, representing an increase of 18% year-over-year; first quarter current GAAP RPO totaled $454.0 million, representing an increase of 22% year-over-year. First quarter non-GAAP RPO totaled $770.9 million, representing an increase of 17% year-over-year; first quarter current non-GAAP RPO totaled $473.6 million, representing an increase of 20% year-over-year. SAN FRANCISCO, May 30, 2024 (GLOBE NEWSWIRE) — HashiCorp, Inc. (NASDAQ: HCP), a leading provider of multi-cloud infrastructure automation software, today announced...

Day: May 30, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice